ArticleJournal of Cancer2011
Immune effects of trastuzumab.
Article in Journal of Cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 44 citations in OpenAlex.
- The impact of the PI3K/AKT/mTOR signaling pathway on trastuzumab resistance in HER2-positive gastric cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Optimizing neoadjuvant treatment in HER2-positive breast cancer: the role of HER2, HR, PD-L1 expression and regimen selection.Future oncology (London, England) · 2025Article
- Anionic lipids direct efficient microfluidic encapsulation of stable and functionally active proteins in lipid nanoparticles.Communications materials · 2025Article
- A Non-Canonical p75HER2 Signaling Pathway Underlying Trastuzumab Action and Resistance in Breast Cancer.Cells · 2024Article
- Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer.Molecular cancer · 2024Review
- Exploring the human microbiome - A step forward for precision medicine in breast cancer.Cancer reports (Hoboken, N.J.) · 2023Review
- Article
- Strategies to functionalize extracellular vesicles against HER2 for anticancer activity.Extracellular vesicles and circulating nucleic acids · 2022Review
- Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Article
- Trastuzumab in the Treatment of Pregnant Breast Cancer Patients - an Overview of the Literature.Geburtshilfe und Frauenheilkunde · 2019Article
- CAR-T with License to Kill Solid Tumors in Search of a Winning Strategy.International journal of molecular sciences · 2019Review
- Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer.Cancers · 2018Review
- Targeting HER2 by Combination Therapies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Article
- The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2.BMC cancer · 2018Article
- Ultrasound-mediated microbubble destruction: a new method in cancer immunotherapy.OncoTargets and therapy · 2018Review
- The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.Endocrine-related cancer · 2017Review
- Article
- Targeting Tumors with Small Molecule Peptides.Current cancer drug targets · 2016Review
- Adaptive immunity in cancer immunology and therapeutics.Ecancermedicalscience · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trastuzumab's targeted therapy has become a stronghold for human epidermal growth factor receptor 2 positive breast cancer patients. This humanized monoclonal antibody binds to the extracellular juxta-membrane domain of HER2 and inhibits the proliferation and survival of HER2 dependent cancer cells. The ways by which this molecule exerts its action have been partially elucidated but several new mechanisms are being constantly identified. Several new agents are being introduced that interfere with HER2. Several new immunotherapy strategies are being introduced in order to direct the immune system against cells and tissues that aberrantly overexpressed HER2. We review the strategies currently adopted and those suggested against HER2 expressing tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.